The apparently discordant expression we observed between BTK protein expression in GBM-derived stem-like cell lines and tumour tissue is important to resolve because BTK is presumed to be expressed in GBM cancer cells, and as such, BTK inhibitors are being developed in clinical trials for GBM patients (NCT03535350). Here, BTK is linked to cancer.